International drugmaker Teva Pharmaceuticals has turned its back on its rocky deal with Mylan and hooked up with another business partner. The abrupt about-face today redirects the $40.1 billion offered to Mylan to a $40.5 billion buyout of Allergan generics and catapults the already-top-selling generics business well ahead of its rivals. "What we are doing here will enable Teva to be one of the winners of the ever-changing pharmaceutical industry," CEO Erez Vigodman said in a Wall Street Journal report. Teva, the Israeli corporation that employs 1,700 people in Chester County, will pay $33.75 billion in cash and give Allergan a 10 percent stake in its new parent company through shares currently valued at $6.75 billion. Teva currently ranks first in global generic drug sales at $9.1 billion last year, while Allergan ranks third at $6.6 billion. Mylan is fourth at $6.5 billion.